Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report)’s share price was up 1.6% on Thursday . The stock traded as high as $10.99 and last traded at $10.89. 101 shares traded hands during mid-day trading, a decline of 98% from the average daily volume of 5,519 shares. The stock had previously closed at $10.72.
Drugs Made in America Acquisition Trading Down 1.2%
The company’s 50-day moving average price is $10.81 and its 200-day moving average price is $10.64.
Drugs Made in America Acquisition Company Profile
Drugs Made in America Acquisition Corp is a special purpose acquisition company incorporated in Delaware and traded on the NASDAQ under the ticker DMAAU. It was organized to raise capital through its initial public offering and to identify and complete a business combination with one or more U.S.-based pharmaceutical or biotechnology companies.
The company’s investment mandate is focused on target businesses engaged in the development, manufacture or commercialization of finished dosage pharmaceuticals, active pharmaceutical ingredients and related medical products for the American market.
Further Reading
- Five stocks we like better than Drugs Made in America Acquisition
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
